Cover Image
Market Research Report

Prosthetic Heart Valves - Medical Devices Pipeline Assessment, 2018

Published by GlobalData Product code 654785
Published Content info 437 Pages
Delivery time: 1-2 business days
Price
Back to Top
Prosthetic Heart Valves - Medical Devices Pipeline Assessment, 2018
Published: June 8, 2018 Content info: 437 Pages
Description

GlobalData's Medical Devices sector report, "Prosthetic Heart Valves - Medical Devices Pipeline Assessment, 2018" provides an overview of Prosthetic Heart Valves currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Prosthetic Heart Valves pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Prosthetic Heart Valves under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Prosthetic Heart Valves and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Prosthetic Heart Valves under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
Product Code: GDME0601EPD

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 8
  • 1.2 List of Figures 21

2 Introduction 22

  • 2.1 Prosthetic Heart Valves Overview 22

3 Products under Development 24

  • 3.1 Prosthetic Heart Valves - Pipeline Products by Stage of Development 24
  • 3.2 Prosthetic Heart Valves - Pipeline Products by Segment 25
  • 3.3 Prosthetic Heart Valves - Pipeline Products by Territory 26
  • 3.4 Prosthetic Heart Valves - Pipeline Products by Regulatory Path 28
  • 3.5 Prosthetic Heart Valves - Pipeline Products by Estimated Approval Date 29
  • 3.6 Prosthetic Heart Valves - Ongoing Clinical Trials 30

4 Prosthetic Heart Valves - Pipeline Products under Development by Companies 31

  • 4.1 Prosthetic Heart Valves Companies - Pipeline Products by Stage of Development 31
  • 4.2 Prosthetic Heart Valves - Pipeline Products by Stage of Development 35

5 Prosthetic Heart Valves Companies and Product Overview 41

  • 5.1 4C Medical Technologies Inc Company Overview 41
  • 5.2 Abbott Vascular Inc Company Overview 42
  • 5.3 Admedus Ltd Company Overview 45
  • 5.4 Aegis Surgical Limited Company Overview 46
  • 5.5 Annulon Company Overview 47
  • 5.6 AorTech International Plc Company Overview 48
  • 5.7 AorTx, Inc. Company Overview 49
  • 5.8 Arbor Surgical Technologies, Inc. Company Overview 50
  • 5.9 Boston Children's Hospital Company Overview 51
  • 5.10 Boston Scientific Corp Company Overview 52
  • 5.11 Carena Healthcare Ltd Company Overview 75
  • 5.12 Cephea Valve Technologies, Inc. Company Overview 76
  • 5.13 Children's Hospital Boston Company Overview 77
  • 5.14 Clemson University Company Overview 79
  • 5.15 Colibri Heart Valve, LLC Company Overview 80
  • 5.16 Collagen Solutions Plc Company Overview 89
  • 5.17 Colorado State University Company Overview 90
  • 5.18 CorMatrix Cardiovascular Inc Company Overview 91
  • 5.19 CryoLife Inc Company Overview 97
  • 5.20 Cytograft Tissue Engineering Inc (Inactive) Company Overview 99
  • 5.21 Daidalos Solutions BV Company Overview 100
  • 5.22 Direct Flow Medical Inc (Inactive) Company Overview 104
  • 5.23 DSM Dyneema BV Company Overview 108
  • 5.24 Dura LLC Company Overview 109
  • 5.25 Edwards Lifesciences Corp Company Overview 111
  • 5.26 Emory University Company Overview 139
  • 5.27 Endoluminal Technology Research, LLC Company Overview 140
  • 5.28 Florida International University Company Overview 142
  • 5.29 Georgia Institute of Technology Company Overview 144
  • 5.30 Hancock Jaffe Laboratories Inc Company Overview 145
  • 5.31 HighLife SAS Company Overview 147
  • 5.32 HLT, Inc. Company Overview 150
  • 5.33 Hocor Cardiovascular Technologies, LLC Company Overview 153
  • 5.34 Innovia LLC Company Overview 154
  • 5.35 JC Medical, Inc. Company Overview 156
  • 5.36 JenaValve Technology GmbH Company Overview 161
  • 5.37 Leman Cardiovascular SA Company Overview 164
  • 5.38 LivaNova PLC Company Overview 165
  • 5.39 Mayo Clinic Company Overview 175
  • 5.40 Medi-Line S.A. Company Overview 176
  • 5.41 Medtronic plc Company Overview 177
  • 5.42 Meril Life Sciences Pvt Ltd Company Overview 191
  • 5.43 Micro Interventional Devices, Inc. Company Overview 192
  • 5.44 MicroPort Scientific Corp Company Overview 193
  • 5.45 Mitralix Ltd. Company Overview 197
  • 5.46 MitrAssist Ltd. Company Overview 198
  • 5.47 Mitricares Company Overview 199
  • 5.48 MValve Technologies Ltd. Company Overview 200
  • 5.49 NaviGate Cardiac Structures, Inc. Company Overview 203
  • 5.50 Neovasc Inc Company Overview 207
  • 5.51 Peca Labs, Inc. Company Overview 210
  • 5.52 PolyNova Cardiovascular LLC (Inactive) Company Overview 211
  • 5.53 Polyvascular Corp Company Overview 212
  • 5.54 Rambam Health Care Campus Company Overview 213
  • 5.55 RegenaGraft Company Overview 214
  • 5.56 ReValve Med Inc Company Overview 215
  • 5.57 Revivicor Inc Company Overview 216
  • 5.58 SAS Cormove Company Overview 217
  • 5.59 Sino Medical Sciences Technology Inc Company Overview 218
  • 5.60 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview 219
  • 5.61 St. Jude Medical LLC Company Overview 220
  • 5.62 Stellenbosch University Company Overview 226
  • 5.63 Strait Access Technologies (Pty) Ltd Company Overview 227
  • 5.64 Symetis SA Company Overview 229
  • 5.65 Thoratec Corp Company Overview 242
  • 5.66 Thubrikar Aortic Valve, Inc. Company Overview 243
  • 5.67 Tissue Regenix Ltd Company Overview 245
  • 5.68 Trinity College Dublin Company Overview 247
  • 5.69 TTK Healthcare Ltd Company Overview 248
  • 5.70 University College London Company Overview 249
  • 5.71 University of Arizona Company Overview 252
  • 5.72 University of California Company Overview 253
  • 5.73 University of California Irvine Company Overview 254
  • 5.74 University of California San Francisco Company Overview 256
  • 5.75 University of Cambridge Company Overview 257
  • 5.76 University of Colorado Company Overview 259
  • 5.77 University of Florida Company Overview 260
  • 5.78 University of Iowa Company Overview 261
  • 5.79 University of Minnesota Company Overview 263
  • 5.80 University of Pennsylvania Company Overview 264
  • 5.81 University of South Florida Company Overview 267
  • 5.82 University of Zurich Company Overview 268
  • 5.83 Valtech Cardio Ltd Company Overview 269
  • 5.84 ValveXchange, Inc. (Inactive) Company Overview 272
  • 5.85 Vascular Concepts Ltd Company Overview 275
  • 5.86 Venus MedTech Company Overview 276
  • 5.87 VueKlar Cardiovascular Ltd (Inactive) Company Overview 283
  • 5.88 Xeltis AG Company Overview 284

6 Prosthetic Heart Valves- Recent Developments 289

  • 6.1 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 289
  • 6.2 May 31, 2018: JC Medical Announces First-in-Human Treatment with the Unique Transfemoral J-Valve TAVI Device for Aortic Regurgitation 289
  • 6.3 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results 290
  • 6.4 May 23, 2018: Abbott's Investigational Tendyne Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study 292
  • 6.5 May 22, 2018: Treatment with Abbott s Portico Transcatheter Aortic Valve Showed Portico is Safe and Reduces Severe Aortic Stenosis at 30 Days in Real-World Setting 294
  • 6.6 May 22, 2018: Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve 295
  • 6.7 May 22, 2018: Admedus: TAVR Progress Continues With Filing of New Provisional Patents 296
  • 6.8 May 21, 2018: Edwards Announces Key Events For EuroPCR 2018 297
  • 6.9 May 21, 2018: NaviGate Cardiac Structures reports "excellent valvular function" at 1-year follow-up of first patient to receive GATE tricuspid valved stent via transjugular access 297
  • 6.10 May 17, 2018: MicroPort CardioFlow Releases One-year Clinical Outcome of VitaFlow 299
  • 6.11 May 17, 2018: MicroPort CardioFlow Attends Fourth China Valve (Hangzhou) Meeting 300
  • 6.12 May 17, 2018: Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC 300
  • 6.13 May 16, 2018: Boston Scientific Announces Schedule of Presentations at EuroPCR 2018 301
  • 6.14 May 16, 2018: Boston Scientific Announces Schedule of Presentations at EuroPCR 2018 302
  • 6.15 May 10, 2018: Neovasc Announces Results for the First Quarter 2018 302
  • 6.16 May 09, 2018: Computer-Designed Customized Regenerative Heart Valves 306
  • 6.17 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 307
  • 6.18 May 04, 2018: Colibri Heart Valve Continues Enrollment in Clinical Feasibility Study of Second-Generation TAVI System 307
  • 6.19 May 02, 2018: CryoLife Announces First Quarter 2018 Financial Results 308

7 Appendix 432

  • 7.1 Methodology 432
  • 7.2 About GlobalData 435
  • 7.3 Contact Us 435
  • 7.4 Disclaimer 435

List of Tables

  • Table 1: Prosthetic Heart Valves - Pipeline Products by Stage of Development 26
  • Table 2: Prosthetic Heart Valves - Pipeline Products by Segment 27
  • Table 3: Prosthetic Heart Valves - Pipeline Products by Territory 28
  • Table 4: Prosthetic Heart Valves - Pipeline Products by Regulatory Path 30
  • Table 5: Prosthetic Heart Valves - Pipeline Products by Estimated Approval Date 31
  • Table 6: Prosthetic Heart Valves - Ongoing Clinical Trials 32
  • Table 7: Prosthetic Heart Valves Companies - Pipeline Products by Stage of Development 33
  • Table 8: Prosthetic Heart Valves - Pipeline Products by Stage of Development 37
  • Table 9: 4C Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 10: AltaValve - Product Status 43
  • Table 11: AltaValve - Product Description 43
  • Table 12: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 13: Tendyne Bioprosthetic Mitral Valve Implantation System - Product Status 44
  • Table 14: Tendyne Bioprosthetic Mitral Valve Implantation System - Product Description 44
  • Table 15: Abbott Vascular Inc - Ongoing Clinical Trials Overview 45
  • Table 16: Tendyne Bioprosthetic Mitral Valve Implantation System - Expanded Clinical Study of the Tendyne Mitral Valve System 46
  • Table 17: Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 18: Transcatheter Aortic Valve Replacement Device - Product Status 47
  • Table 19: Transcatheter Aortic Valve Replacement Device - Product Description 47
  • Table 20: Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 21: pTAo-TAVR - Product Status 48
  • Table 22: pTAo-TAVR - Product Description 48
  • Table 23: Annulon Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 24: Mitral Valve Replacement Device - Product Status 49
  • Table 25: Mitral Valve Replacement Device - Product Description 49
  • Table 26: AorTech International Plc Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 27: AorTech Polymer Valve - Product Status 50
  • Table 28: AorTech Polymer Valve - Product Description 50
  • Table 29: AorTx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 30: AorTx Valve - Product Status 51
  • Table 31: AorTx Valve - Product Description 51
  • Table 32: Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 33: Trilogy Aortic Valve System - Product Status 52
  • Table 34: Trilogy Aortic Valve System - Product Description 52
  • Table 35: Boston Children's Hospital Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 36: Pulmonary Valve Replacement Device - Product Status 53
  • Table 37: Pulmonary Valve Replacement Device - Product Description 53
  • Table 38: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 39: ACURATE TAVR - Product Status 54
  • Table 40: ACURATE TAVR - Product Description 55
  • Table 41: Gen 4 Lotus Valve System - Product Status 55
  • Table 42: Gen 4 Lotus Valve System - Product Description 55
  • Table 43: Lotus Edge Sheath 15F - Product Status 55
  • Table 44: Lotus Edge Sheath 15F - Product Description 56
  • Table 45: Lotus Edge Valve System - 21 mm - Product Status 56
  • Table 46: Lotus Edge Valve System - 21 mm - Product Description 56
  • Table 47: Lotus Edge Valve System - 23 mm - Product Status 57
  • Table 48: Lotus Edge Valve System - 23 mm - Product Description 57
  • Table 49: Lotus Edge Valve System - 25 mm - Product Status 57
  • Table 50: Lotus Edge Valve System - 25 mm - Product Description 58
  • Table 51: Lotus Edge Valve System - 27 mm - Product Status 58
  • Table 52: Lotus Edge Valve System - 27 mm - Product Description 58
  • Table 53: Lotus Edge Valve System - 29 mm - Product Status 59
  • Table 54: Lotus Edge Valve System - 29 mm - Product Description 59
  • Table 55: Lotus Valve System - 21 mm - Product Status 59
  • Table 56: Lotus Valve System - 21 mm - Product Description 60
  • Table 57: Lotus Valve System - 23 mm - Product Status 60
  • Table 58: Lotus Valve System - 23 mm - Product Description 61
  • Table 59: Lotus Valve System - 25 mm - Product Status 61
  • Table 60: Lotus Valve System - 25 mm - Product Description 62
  • Table 61: Lotus Valve System - 27 mm - Product Status 62
  • Table 62: Lotus Valve System - 27 mm - Product Description 62
  • Table 63: Lotus Valve System - 29 mm - Product Status 63
  • Table 64: Lotus Valve System - 29 mm - Product Description 63
  • Table 65: Transaortic Sheath - Product Status 63
  • Table 66: Transaortic Sheath - Product Description 64
  • Table 67: Boston Scientific Corp - Ongoing Clinical Trials Overview 65
  • Table 68: Lotus Valve System - 23 mm - Experience with Percutaneous Transcatheter Aortic Valve Implantation in Patients with Symptomatic Aortic Valve Disease in Two German Centers 67
  • Table 69: Lotus Valve System - 23 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 67
  • Table 70: Lotus Valve System - 23 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 67
  • Table 71: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 68
  • Table 72: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 68
  • Table 73: Lotus Valve System - 23 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 68
  • Table 74: Lotus Valve System - 27 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 69
  • Table 75: Lotus Valve System - 27 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 69
  • Table 76: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 69
  • Table 77: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 70
  • Table 78: Lotus Valve System - 27 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 70
  • Table 79: Lotus Valve System - 25 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 71
  • Table 80: Lotus Valve System - 25 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 71
  • Table 81: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 71
  • Table 82: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 72
  • Table 83: Lotus Valve System - 25 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 72
  • Table 84: Lotus Valve System - 21 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 73
  • Table 85: Lotus Valve System - 21 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 73
  • Table 86: Lotus Valve System - 21 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 73
  • Table 87: Lotus Valve System - 29 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 74
  • Table 88: Lotus Valve System - 29 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 74

List of Figures

  • Figure 1: Prosthetic Heart Valves - Pipeline Products by Stage of Development 26
  • Figure 2: Prosthetic Heart Valves - Pipeline Products by Segment 27
  • Figure 3: Prosthetic Heart Valves - Pipeline Products by Territory 28
  • Figure 4: Prosthetic Heart Valves - Pipeline Products by Regulatory Path 30
  • Figure 5: Prosthetic Heart Valves - Pipeline Products by Estimated Approval Date 31
  • Figure 6: Prosthetic Heart Valves - Ongoing Clinical Trials 32
Back to Top